Cefonicid AHFS/Drugs.com Micromedex Detailed Consumer Information MedlinePlus a601206 ATC code
(6R ,7R )-7-[(2R )-2-hydroxy-2-phenylacetyl)amino]-8-oxo- 3-{[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl}- 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number PubChem CID ChemSpider UNII KEGG ChEBI ChEMBL CompTox Dashboard (EPA ) Formula C 18 H 18 N 6 O 8 S 3 Molar mass 542.56 g·mol−1 3D model (JSmol)
O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@H](O)c3ccccc3)CSc4nnnn4CS(=O)(=O)O)C(=O)O
InChI=1S/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1
Y Key:DYAIAHUQIPBDIP-AXAPSJFSSA-N
Y
(verify)
Cefonicide (or cefonicid ) is a cephalosporin antibiotic.[ 1]
It has a density of 1.92g/cm3 .
Synthesis
Injectable semi-synthetic cephalosporin antibiotic related to cefamandole , q.v.
Cefonicid synthesis:[ 2] [ 3] [ 4]
Cefonicid is synthesized conveniently by nucleophilic displacement of the 3-acetoxy moiety of 1 with the appropriately substituted tetrazole thiole 2 . The mandelic acid amide C-7 side chain is reminiscent of cefamandole .
See also
References
^ Saltiel E, Brogden RN (September 1986). "Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use". Drugs . 32 (3): 222– 59. doi:10.2165/00003495-198632030-00002 . PMID 3530703 . S2CID 243051006 .
^ DE 2611270 , Berges, David Alan, "Cephalosporin-Derivate [Cephalosporin derivatives]", published 1976-09-30, assigned to SmithKline Corp.
^ D. A. Berges, U.S. patent 4,048,311 (1977 to Smith Kline).
^ U.S. patent 4,093,723 , U.S. patent 4,159,373 (1978, 1979 both to Smith Kline).
Antibacterials active on the cell wall and envelope (J01C-J01D)
β-lactams(inhibit synthesis of peptidoglycan layer of bacterial cell wall by binding to and inhibiting PBPs, a group ofD -alanyl-D -alanine transpeptidases)
Penicillins (Penams)
Narrow spectrum
β-lactamase sensitive (1st generation) β-lactamase resistant (2nd generation)
Extended spectrum
Aminopenicillins (3rd generation) Carboxypenicillins (4th generation) Ureidopenicillins (4th generation) Other
Carbapenems / Penems
Carbapenems (Ertapenem
Antipseudomonal (Doripenem
Imipenem
Meropenem )
Biapenem‡
Panipenem)
Penems (Faropenem
Ritipenem§
Sulopenem)
Cephems Cephalosporins Cephamycins Carbacephems
1st generation 2nd generation 3rd generation 4th generation
Cefepime
Cefozopran‡
Cefpirome
Cefquinome‡
5th generation
Ceftaroline fosamil
Ceftolozane
Ceftobiprole
Siderophore Veterinary
Ceftiofur
Cefquinome
Cefovecin
Monobactams
Aztreonam
Tigemonam‡
Carumonam‡
Nocardicin A‡
β-lactamase inhibitors
Penam (Sulbactam
Tazobactam
Enmetazobactam)
Clavam (Clavulanic acid )
non-β-lactam (Avibactam
Durlobactam
Relebactam
Taniborbactam
Vaborbactam)
Combinations
Amoxicillin/clavulanic acid#
Ampicillin/flucloxacillin
Ampicillin/sulbactam (Sultamicillin)
Aztreonam/avibactam
Benzathine benzylpenicillin/procaine benzylpenicillin
Cefepime/enmetazobactam
Cefepime/sulbactam
Cefoperazone/sulbactam
Ceftazidime/avibactam
Ceftolozane/tazobactam
Imipenem/cilastatin#
Imipenem/cilastatin/relebactam
Meropenem/vaborbactam
Panipenem/betamipron
Piperacillin/tazobactam
Sulbactam/durlobactam
Sulopenem/probenecid
Ticarcillin/clavulanic acid
Polypeptides
Lipopeptides
Insert into bacterial cell wall causing perforation and depolarization: Daptomycin
Surfactin
Other
Inhibits PG elongation and crosslinking: Ramoplanin§
Intracellular
Inhibit PG subunit synthesis and transport: NAM synthesis inhibition
DADAL/AR inhibitors
bactoprenol inhibitors
Other
Hydrolyze NAM-NAG
Tyrothricin
Isoniazid #
Teixobactin
# WHO-EM
‡ Withdrawn from market
Clinical trials:
† Phase III
§ Never to phase III